EMA panel backs EU approval of Roche’s Ocrevus for pediatric relapsing MS patients 10+
EMA’s CHMP recommended EU approval of Roche’s Ocrevus IV for relapsing multiple sclerosis in patients aged 10 and older. European Commission decision expected soon; FDA cleared the pediatric use in May 2026. Phase III OPERETTA 2 showed non-inferior relapse control versus fingolimod; 48% lower relapse risk. Disclaimer